Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Immunol. 2012 Jun;24(3):324-31. doi: 10.1016/j.coi.2012.03.009. Epub 2012 Apr 21.

Malaria vaccine development: persistent challenges.

Author information

  • 1Seattle Biomedical Research Institute, 307 Westlake Avenue North, Seattle, WA 98109, USA. ashley.vaughan@seattlebiomed.org

Abstract

There is no licensed vaccine against any human parasitic disease and apicomplexan parasites cause enormous human suffering; the malaria parasite alone kills approximately one million people annually and is the cause of the majority of infection-related deaths in the young. A malaria vaccine is essential if the goal of malaria eradication is to be achieved. Decades ago it was shown that attenuated malaria parasites could induce sterile immunity to infection but progress towards efficacious vaccines for malaria has been slow. However, recent studies have begun to tease out the immune correlates of vaccine-induced sterile protection and essential research on animal models of disease continues to guide vaccine design. Whole parasite approaches to vaccine design through attenuation as well as subunit vaccine development continue to move forward to clinical trials and are showing promising results.

Copyright © 2012 Elsevier Ltd. All rights reserved.

PMID:
22521906
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk